search
Back to results

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (EXPAND)

Primary Purpose

Childhood Absence Epilepsy, Juvenile Absence Epilepsy

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Brivaracetam
Placebo
Sponsored by
UCB Biopharma SRL
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Childhood Absence Epilepsy focused on measuring Brivaracetam, Briviact, Epilepsy, Childhood absence Epilepsy, Juvenile absence epilepsy, CAE, JAE

Eligibility Criteria

2 Years - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Study participant is 2 to 25 years of age inclusive, at the time of signing the informed consent. No study participants from 2 to <4 years of age will be included in Stage 1
  • Study participant is diagnosed with either childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE) as defined by the International League Against Epilepsy (ILAE) criteria
  • Study participants 2 to <4 years of age and participants who had onset of absence seizures at an age younger than 4 years must have a negative glucose transporter type 1 deficiency syndrome (GLUT1DS) genetic test
  • Study participant is untreated with antiepileptic drugs (AEDs) or pretreated for absence seizures with a maximum of 2 historical AEDs, but without AED treatment for a period of at least 5 half-lives of the AED before randomization into this study. The UCB study physician should be consulted if in doubt
  • Study participant has electroencephalogram (EEG) evidence of bilateral synchronous, symmetric generalized paroxysmal spike waves (2.5-6 hertz) with normal background activity and with at least 1 electrographically recorded seizure lasting 3 seconds or more on a 1-hour EEG with hyperventilation (HV) while awake at Visit 1 (V1), or on a historical EEG up to 12 weeks before enrollment
  • Study participant has a history of clinically evident absence seizures occurring on at least 3 days per week in the 2 weeks prior to enrollment
  • Study participant is without treatment with psychoactive drugs or on a stable dose for at least 2 weeks prior to randomization
  • Study participant has normal neurological examination, head size, development and cognition
  • Body weight is ≥9 kg
  • Male and female

    a) A sexually active male study participant must agree to use contraception during the treatment period and for at least 2 days, corresponding to the time needed to eliminate study treatment, after the last dose of study treatment and refrain from donating sperm during this period b) A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: The study participant is premenarchial OR A woman of childbearing potential (WOCBP) who agrees to follow the contraceptive guidance during the treatment period and for at least 2 days after the last dose of study treatment, corresponding to the time needed to eliminate study treatment

  • Study participant is capable of and provides consent/assent, and the study participant's parent/legal representative/caregiver provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion Criteria:

  • Study participant has a history of nonfebrile seizures other than absence seizures (eg, generalized tonic-clonic seizures or myoclonic seizures)
  • Study participant has a history of absence status epilepticus
  • Study participant has a history or presence of paroxysmal nonepileptic seizures
  • Study participant has a clinically relevant electrocardiogram (ECG) abnormality in the opinion of the Principal Investigator
  • Study participant has hepatic impairment (Child Pugh Score A, B, or C) based on the Investigator's assessment
  • Study participant has a history of major psychiatric disease or any clinically significant medical condition that would preclude appropriate study participation
  • Study participant has active suicidal ideation prior to study entry as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS; for study participants 6 years or older) or clinical judgement (for study participants younger than 6 years). The study participant should be referred immediately to a Mental Healthcare Professional
  • Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt). The study participant should be immediately evaluated by a Mental Healthcare Professional to address safety concerns
  • Study participant with known fructose intolerance or hypersensitivity of any of the ingredients in brivaracetam oral solution
  • Study participant has end-stage kidney disease requiring dialysis
  • Concomitant use of rifampicin/rifampin; prior use must have been stopped at least 2 months before randomization
  • Concomitant use of strong CYP2C19 inhibitors like fluconazole, fluoxetine and fluvoxamine, prior use must have been stopped at least 1 week before randomization
  • Study participant has participated in another study of an investigational medicinal product (IMP; and/or an investigational device) within the previous 30 days prior to informed consent
  • Study participant has clinical or EEG findings not consistent with a diagnosis of childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE)

Sites / Locations

  • N01269 115Recruiting
  • N01269 118
  • N01269 105Recruiting
  • N01269 116Recruiting
  • N01269 103Recruiting
  • N01269 111Recruiting
  • N01269 101Recruiting
  • N01269 104Recruiting
  • N01269 110Recruiting
  • N01269 100Recruiting
  • N01269 109Recruiting
  • N01269 106
  • N01269 203Recruiting
  • N01269 202Recruiting
  • N01269 200Recruiting
  • N01269 201Recruiting
  • N01269 301Recruiting
  • N01269 300Recruiting
  • N01269 400Recruiting
  • N01269 401Recruiting
  • N01269 402Recruiting
  • N01269 403Recruiting
  • N01269 405Recruiting
  • N01269 323Recruiting
  • N01269 321Recruiting
  • N01269 324Recruiting
  • N01269 320Recruiting
  • N01269 322Recruiting
  • N01269 325Recruiting
  • N01269 326Recruiting
  • N01269 533
  • N01269 530
  • N01269 534
  • N01269 531
  • N01269 532
  • N01269 562Recruiting
  • N01269 563Recruiting
  • N01269 560Recruiting
  • N01269 561Recruiting
  • N01269 632Recruiting
  • N01269 630Recruiting
  • N01269 631Recruiting
  • N01269 351Recruiting
  • N01269 353Recruiting
  • N01269 354Recruiting
  • N01269 600
  • N01269 601
  • N01269 604
  • N01269 608Recruiting
  • N01269 603Recruiting
  • N01269 606Recruiting
  • N01269 607
  • N01269 602

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Brivaracetam 200 mg

Placebo to 200 mg brivaracetam

Brivaracetam 100 mg

Placebo to 100 mg brivaracetam

Optimal dose of BRV (defined following Stage 1)

Placebo to BRV optimal dose (defined following Stage 1)

Brivaracetam received during RDW

Placebo received during RDW

Arm Description

Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to brivaracetam (BRV) 200mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period.

Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to 'placebo to BRV 200mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 200mg/day (or equivalent dose) during the AT period.

Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to BRV 100mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period.

Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to 'placebo to BRV 100mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 100mg/day (or equivalent dose) during the AT period.

Placebo-Controlled (PC) and Active Treatment Period (AT): Stage 2: Study participants will be randomized in Stage 2 to receive a fixed dose of the optimal dose of brivaracetam (defined following Stage 1). Study participants randomized to the BRV optimal dose will receive this dose during the 2-week PC period and subsequent 11-week AT period.

Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 2: Study participants will be randomized in Stage 2 of the study to 'placebo to BRV optimal dose'. Study participants randomized to placebo to brivaracetam (BRV) optimal dose will receive placebo during the PC period followed by BRV optimal dose during the AT period.

Randomized Withdrawal (RDW) Period: Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Participants who are randomized to this arm will continue on the Brivaracetam dose they were receiving in the AT period.

Randomized Withdrawal (RDW) Period: Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Study participants who are randomized to the placebo arm in the RDW Period will be tapered down to 0 mg and receive 0 mg for 2 weeks.

Outcomes

Primary Outcome Measures

Percentage of participants who met the criteria for absence seizure freedom within 4 days prior to or during the 24-hour ambulatory electroencephalogram (EEG) at Day 14
A 24-hour ambulatory electroencephalogram (EEG) will be performed at day 14. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include hyperventilation as a standard provocation test at the beginning of the EEG. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.

Secondary Outcome Measures

Percentage of participants who met the criteria for absence seizure freedom during the randomized withdrawal (RDW) period as determined by electroencephalogram (EEG)
Study participants (or their care givers) who believe they are experiencing a recurrence of absence seizures will contact the clinical site for a 1-hour EEG (with hyperventilation (HV)). If no absence seizure is observed during this 1hr EEG (locally read), the study participant will receive a 24-hour ambulatory EEG. If an absence seizure is observed during either EEG, the study participant will be considered as not Absence seizure free and leave the study. If no absence seizures are determined by 1/24hr ambulatory EEG the participant will conduct a 24-hour EEG at week 17. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include HV as a standard provocation test at the beginning of the EEG.
Percent change from Baseline to Day 14 in number of absence seizures on 24-hour ambulatory electroencephalogram (EEG)
A 24-hour ambulatory electroencephalogram (EEG) will be performed at baseline and day 14. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include hyperventilation as a standard provocation test at the beginning of the EEG. This endpoint is the difference between the number of seizures at baseline and Day 14.
Percentage of participants who met the criteria for absence seizure freedom based on diary during the 4 days prior to the visit at Day 14
During the study subjects will keep a diary to record daily seizure activity from Visit 1 until end of the randomized withdrawal (RDW) Period. Each seizure type experienced will be recorded. The last 4 study days prior to Day 14 EEG are used for this endpoint. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.
Percentage of participants who met the criteria for absence seizure freedom on 24-hour ambulatory electroencephalogram (EEG) at Week 12
A 24-hour ambulatory electroencephalogram (EEG) will be performed at day 14. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include hyperventilation as a standard provocation test at the beginning of the EEG. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.
Percentage of participants who met the criteria for absence seizure freedom based on diary during the 4 days prior to the visit at Week 12
During the study subjects will keep a diary to record daily seizure activity from Visit 1 until end of the randomized withdrawal (RDW) Period. Each seizure type experienced will be recorded. The last 4 study days prior to Week 12 EEG are used for this endpoint. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP).
Percentage of participants with treatment-emergent adverse events (TEAEs) leading to discontinuation of study treatment
An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP).
Percentage of participants with serious adverse events (SAEs) during the study
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: Results in death Is life-threatening Requires in patient hospitalization or prolongation of existing hospitalization Is a congenital anomaly or birth defect Results in permanent or significant disability/incapacity Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above
Percentage of participants with drug-related treatment-emergent adverse events (TEAEs) during the study
An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP). 'Drug related AEs' are the subset of AEs that the investigator considers as related to the study drug.

Full Information

First Posted
December 7, 2020
Last Updated
July 20, 2023
Sponsor
UCB Biopharma SRL
search

1. Study Identification

Unique Protocol Identification Number
NCT04666610
Brief Title
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Acronym
EXPAND
Official Title
A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 29, 2021 (Actual)
Primary Completion Date
February 25, 2026 (Anticipated)
Study Completion Date
February 25, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
UCB Biopharma SRL

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Keywords
Brivaracetam, Briviact, Epilepsy, Childhood absence Epilepsy, Juvenile absence epilepsy, CAE, JAE

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Brivaracetam 200 mg
Arm Type
Experimental
Arm Description
Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to brivaracetam (BRV) 200mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period.
Arm Title
Placebo to 200 mg brivaracetam
Arm Type
Experimental
Arm Description
Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to 'placebo to BRV 200mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 200mg/day (or equivalent dose) during the AT period.
Arm Title
Brivaracetam 100 mg
Arm Type
Experimental
Arm Description
Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to BRV 100mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period.
Arm Title
Placebo to 100 mg brivaracetam
Arm Type
Experimental
Arm Description
Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to 'placebo to BRV 100mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 100mg/day (or equivalent dose) during the AT period.
Arm Title
Optimal dose of BRV (defined following Stage 1)
Arm Type
Experimental
Arm Description
Placebo-Controlled (PC) and Active Treatment Period (AT): Stage 2: Study participants will be randomized in Stage 2 to receive a fixed dose of the optimal dose of brivaracetam (defined following Stage 1). Study participants randomized to the BRV optimal dose will receive this dose during the 2-week PC period and subsequent 11-week AT period.
Arm Title
Placebo to BRV optimal dose (defined following Stage 1)
Arm Type
Experimental
Arm Description
Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 2: Study participants will be randomized in Stage 2 of the study to 'placebo to BRV optimal dose'. Study participants randomized to placebo to brivaracetam (BRV) optimal dose will receive placebo during the PC period followed by BRV optimal dose during the AT period.
Arm Title
Brivaracetam received during RDW
Arm Type
Experimental
Arm Description
Randomized Withdrawal (RDW) Period: Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Participants who are randomized to this arm will continue on the Brivaracetam dose they were receiving in the AT period.
Arm Title
Placebo received during RDW
Arm Type
Experimental
Arm Description
Randomized Withdrawal (RDW) Period: Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Study participants who are randomized to the placebo arm in the RDW Period will be tapered down to 0 mg and receive 0 mg for 2 weeks.
Intervention Type
Drug
Intervention Name(s)
Brivaracetam
Other Intervention Name(s)
BRV
Intervention Description
Pharmaceutical form: Oral solution Route of administration: Oral use Brivaracetam (oral solution [10 mg/ml, 5 mg/ml or 2.5 mg/ml] will be administered.
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
PBO
Intervention Description
Subjects will receive placebo at pre-specified time-points to maintain the blinding.
Primary Outcome Measure Information:
Title
Percentage of participants who met the criteria for absence seizure freedom within 4 days prior to or during the 24-hour ambulatory electroencephalogram (EEG) at Day 14
Description
A 24-hour ambulatory electroencephalogram (EEG) will be performed at day 14. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include hyperventilation as a standard provocation test at the beginning of the EEG. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.
Time Frame
Day 14
Secondary Outcome Measure Information:
Title
Percentage of participants who met the criteria for absence seizure freedom during the randomized withdrawal (RDW) period as determined by electroencephalogram (EEG)
Description
Study participants (or their care givers) who believe they are experiencing a recurrence of absence seizures will contact the clinical site for a 1-hour EEG (with hyperventilation (HV)). If no absence seizure is observed during this 1hr EEG (locally read), the study participant will receive a 24-hour ambulatory EEG. If an absence seizure is observed during either EEG, the study participant will be considered as not Absence seizure free and leave the study. If no absence seizures are determined by 1/24hr ambulatory EEG the participant will conduct a 24-hour EEG at week 17. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include HV as a standard provocation test at the beginning of the EEG.
Time Frame
From Week 13 to Week 17
Title
Percent change from Baseline to Day 14 in number of absence seizures on 24-hour ambulatory electroencephalogram (EEG)
Description
A 24-hour ambulatory electroencephalogram (EEG) will be performed at baseline and day 14. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include hyperventilation as a standard provocation test at the beginning of the EEG. This endpoint is the difference between the number of seizures at baseline and Day 14.
Time Frame
From Baseline to Day 14
Title
Percentage of participants who met the criteria for absence seizure freedom based on diary during the 4 days prior to the visit at Day 14
Description
During the study subjects will keep a diary to record daily seizure activity from Visit 1 until end of the randomized withdrawal (RDW) Period. Each seizure type experienced will be recorded. The last 4 study days prior to Day 14 EEG are used for this endpoint. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.
Time Frame
Day 14
Title
Percentage of participants who met the criteria for absence seizure freedom on 24-hour ambulatory electroencephalogram (EEG) at Week 12
Description
A 24-hour ambulatory electroencephalogram (EEG) will be performed at day 14. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include hyperventilation as a standard provocation test at the beginning of the EEG. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.
Time Frame
Week 12
Title
Percentage of participants who met the criteria for absence seizure freedom based on diary during the 4 days prior to the visit at Week 12
Description
During the study subjects will keep a diary to record daily seizure activity from Visit 1 until end of the randomized withdrawal (RDW) Period. Each seizure type experienced will be recorded. The last 4 study days prior to Week 12 EEG are used for this endpoint. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.
Time Frame
Week 12
Title
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
Description
An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP).
Time Frame
From Day 1 until End of Safety Follow-Up (up to Week 23)
Title
Percentage of participants with treatment-emergent adverse events (TEAEs) leading to discontinuation of study treatment
Description
An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP).
Time Frame
From Day 1 until End of Down Titration Period (up to Week 21)
Title
Percentage of participants with serious adverse events (SAEs) during the study
Description
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: Results in death Is life-threatening Requires in patient hospitalization or prolongation of existing hospitalization Is a congenital anomaly or birth defect Results in permanent or significant disability/incapacity Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above
Time Frame
From Screening Period (Day -14 to Day -2) until End of Safety Follow-Up (up to Week 23)
Title
Percentage of participants with drug-related treatment-emergent adverse events (TEAEs) during the study
Description
An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP). 'Drug related AEs' are the subset of AEs that the investigator considers as related to the study drug.
Time Frame
From Baseline (Day -1) until End of Safety Follow-Up (up to Week 23)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Study participant is 2 to 25 years of age inclusive, at the time of signing the informed consent. No study participants from 2 to <4 years of age will be included in Stage 1 Study participant is diagnosed with either childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE) as defined by the International League Against Epilepsy (ILAE) criteria Study participants 2 to <4 years of age and participants who had onset of absence seizures at an age younger than 4 years must have a negative glucose transporter type 1 deficiency syndrome (GLUT1DS) genetic test Study participant is untreated with antiepileptic drugs (AEDs) or pretreated for absence seizures with a maximum of 2 historical AEDs, but without AED treatment for a period of at least 5 half-lives of the AED before randomization into this study. The UCB study physician should be consulted if in doubt Study participant has electroencephalogram (EEG) evidence of bilateral synchronous, symmetric generalized paroxysmal spike waves (2.5-6 hertz) with normal background activity and with at least 1 electrographically recorded seizure lasting 3 seconds or more on a 1-hour EEG with hyperventilation (HV) while awake at Visit 1 (V1), or on a historical EEG up to 12 weeks before enrollment Study participant has a history of clinically evident absence seizures occurring on at least 3 days per week in the 2 weeks prior to enrollment Study participant is without treatment with psychoactive drugs or on a stable dose for at least 2 weeks prior to randomization Study participant has normal neurological examination, head size, development and cognition Body weight is ≥9 kg Male and female a) A sexually active male study participant must agree to use contraception during the treatment period and for at least 2 days, corresponding to the time needed to eliminate study treatment, after the last dose of study treatment and refrain from donating sperm during this period b) A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: The study participant is premenarchial OR A woman of childbearing potential (WOCBP) who agrees to follow the contraceptive guidance during the treatment period and for at least 2 days after the last dose of study treatment, corresponding to the time needed to eliminate study treatment Study participant is capable of and provides consent/assent, and the study participant's parent/legal representative/caregiver provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol Exclusion Criteria: Study participant has a history of nonfebrile seizures other than absence seizures (eg, generalized tonic-clonic seizures or myoclonic seizures) Study participant has a history of absence status epilepticus Study participant has a history or presence of paroxysmal nonepileptic seizures Study participant has a clinically relevant electrocardiogram (ECG) abnormality in the opinion of the Principal Investigator Study participant has hepatic impairment (Child Pugh Score A, B, or C) based on the Investigator's assessment Study participant has a history of major psychiatric disease or any clinically significant medical condition that would preclude appropriate study participation Study participant has active suicidal ideation prior to study entry as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS; for study participants 6 years or older) or clinical judgement (for study participants younger than 6 years). The study participant should be referred immediately to a Mental Healthcare Professional Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt). The study participant should be immediately evaluated by a Mental Healthcare Professional to address safety concerns Study participant with known fructose intolerance or hypersensitivity of any of the ingredients in brivaracetam oral solution Study participant has end-stage kidney disease requiring dialysis Concomitant use of rifampicin/rifampin; prior use must have been stopped at least 2 months before randomization Concomitant use of strong CYP2C19 inhibitors like fluconazole, fluoxetine and fluvoxamine, prior use must have been stopped at least 1 week before randomization Study participant has participated in another study of an investigational medicinal product (IMP; and/or an investigational device) within the previous 30 days prior to informed consent Study participant has clinical or EEG findings not consistent with a diagnosis of childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
UCB Cares
Phone
+1844599
Ext
2273
Email
UCBCares@ucb.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
UCB Cares
Organizational Affiliation
001 844 599 2273 (UCB)
Official's Role
Study Director
Facility Information:
Facility Name
N01269 115
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Individual Site Status
Recruiting
Facility Name
N01269 118
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Individual Site Status
Withdrawn
Facility Name
N01269 105
City
Orange
State/Province
California
ZIP/Postal Code
92868-3874
Country
United States
Individual Site Status
Recruiting
Facility Name
N01269 116
City
Denver
State/Province
Colorado
ZIP/Postal Code
80202
Country
United States
Individual Site Status
Recruiting
Facility Name
N01269 103
City
Loxahatchee Groves
State/Province
Florida
ZIP/Postal Code
33470
Country
United States
Individual Site Status
Recruiting
Facility Name
N01269 111
City
Miami
State/Province
Florida
ZIP/Postal Code
33155-3009
Country
United States
Individual Site Status
Recruiting
Facility Name
N01269 101
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Individual Site Status
Recruiting
Facility Name
N01269 104
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
Individual Site Status
Recruiting
Facility Name
N01269 110
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912
Country
United States
Individual Site Status
Recruiting
Facility Name
N01269 100
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08901
Country
United States
Individual Site Status
Recruiting
Facility Name
N01269 109
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Individual Site Status
Recruiting
Facility Name
N01269 106
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19134
Country
United States
Individual Site Status
Completed
Facility Name
N01269 203
City
Heidelberg
Country
Australia
Individual Site Status
Recruiting
Facility Name
N01269 202
City
Melbourne
Country
Australia
Individual Site Status
Recruiting
Facility Name
N01269 200
City
Randwick
Country
Australia
Individual Site Status
Recruiting
Facility Name
N01269 201
City
South Brisbane
Country
Australia
Individual Site Status
Recruiting
Facility Name
N01269 301
City
Bruxelles
Country
Belgium
Individual Site Status
Recruiting
Facility Name
N01269 300
City
Edegem
Country
Belgium
Individual Site Status
Recruiting
Facility Name
N01269 400
City
Tbilisi
Country
Georgia
Individual Site Status
Recruiting
Facility Name
N01269 401
City
Tbilisi
Country
Georgia
Individual Site Status
Recruiting
Facility Name
N01269 402
City
Tbilisi
Country
Georgia
Individual Site Status
Recruiting
Facility Name
N01269 403
City
Tbilisi
Country
Georgia
Individual Site Status
Recruiting
Facility Name
N01269 405
City
Tbilisi
Country
Georgia
Individual Site Status
Recruiting
Facility Name
N01269 323
City
Messina
Country
Italy
Individual Site Status
Recruiting
Facility Name
N01269 321
City
Milano
Country
Italy
Individual Site Status
Recruiting
Facility Name
N01269 324
City
Milano
Country
Italy
Individual Site Status
Recruiting
Facility Name
N01269 320
City
Pavia
Country
Italy
Individual Site Status
Recruiting
Facility Name
N01269 322
City
Roma
Country
Italy
Individual Site Status
Recruiting
Facility Name
N01269 325
City
Roma
Country
Italy
Individual Site Status
Recruiting
Facility Name
N01269 326
City
Verona
Country
Italy
Individual Site Status
Recruiting
Facility Name
N01269 533
City
Gdansk
Country
Poland
Individual Site Status
Withdrawn
Facility Name
N01269 530
City
Krakow
Country
Poland
Individual Site Status
Withdrawn
Facility Name
N01269 534
City
Lodz
Country
Poland
Individual Site Status
Withdrawn
Facility Name
N01269 531
City
Lublin
Country
Poland
Individual Site Status
Withdrawn
Facility Name
N01269 532
City
Warszawa
Country
Poland
Individual Site Status
Withdrawn
Facility Name
N01269 562
City
Bucuresti
Country
Romania
Individual Site Status
Recruiting
Facility Name
N01269 563
City
Bucuresti
Country
Romania
Individual Site Status
Recruiting
Facility Name
N01269 560
City
Iasi
Country
Romania
Individual Site Status
Recruiting
Facility Name
N01269 561
City
Timişoara, Judeţ Timiş
Country
Romania
Individual Site Status
Recruiting
Facility Name
N01269 632
City
Bardejov
Country
Slovakia
Individual Site Status
Recruiting
Facility Name
N01269 630
City
Dubnica Nad Vahom
Country
Slovakia
Individual Site Status
Recruiting
Facility Name
N01269 631
City
Nove Zamky
Country
Slovakia
Individual Site Status
Recruiting
Facility Name
N01269 351
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
N01269 353
City
Sevilla
Country
Spain
Individual Site Status
Recruiting
Facility Name
N01269 354
City
Terrassa
Country
Spain
Individual Site Status
Recruiting
Facility Name
N01269 600
City
Dnipro
Country
Ukraine
Individual Site Status
Active, not recruiting
Facility Name
N01269 601
City
Dnipro
Country
Ukraine
Individual Site Status
Active, not recruiting
Facility Name
N01269 604
City
Kharkiv
Country
Ukraine
Individual Site Status
Completed
Facility Name
N01269 608
City
Kharkiv
Country
Ukraine
Individual Site Status
Recruiting
Facility Name
N01269 603
City
Kyiv
Country
Ukraine
Individual Site Status
Recruiting
Facility Name
N01269 606
City
Kyiv
Country
Ukraine
Individual Site Status
Recruiting
Facility Name
N01269 607
City
Uzhgorod
Country
Ukraine
Individual Site Status
Completed
Facility Name
N01269 602
City
Vinnytsia
Country
Ukraine
Individual Site Status
Completed

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD Sharing Time Frame
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD Sharing Access Criteria
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD Sharing URL
http://www.Vivli.org
Citations:
PubMed Identifier
35844134
Citation
Bast T, Schulz AL, Floricel F, Morita D, Cleveland JM, Elshoff JP. Efficacy and tolerability of brivaracetam monotherapy in childhood and juvenile absence epilepsy: An innovative adaptive trial design. Epilepsia Open. 2022 Dec;7(4):588-597. doi: 10.1002/epi4.12628. Epub 2022 Aug 4.
Results Reference
result

Learn more about this trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

We'll reach out to this number within 24 hrs